Mural Oncology plc (NASDAQ:MURA - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 392,800 shares, a decline of 15.7% from the September 30th total of 465,800 shares. Approximately 2.5% of the shares of the company are short sold. Based on an average trading volume of 94,200 shares, the short-interest ratio is presently 4.2 days.
Mural Oncology Stock Performance
MURA traded up $0.12 during trading on Monday, reaching $3.63. The stock had a trading volume of 25,100 shares, compared to its average volume of 122,387. Mural Oncology has a 1-year low of $2.88 and a 1-year high of $17.00. The stock has a 50 day moving average of $3.33 and a two-hundred day moving average of $3.40.
Mural Oncology (NASDAQ:MURA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping analysts' consensus estimates of ($1.90) by $0.04. Research analysts predict that Mural Oncology will post -7.59 EPS for the current fiscal year.
Wall Street Analyst Weigh In
MURA has been the subject of several analyst reports. Raymond James initiated coverage on Mural Oncology in a research report on Friday, October 4th. They set a "strong-buy" rating and a $18.00 price objective for the company. HC Wainwright initiated coverage on Mural Oncology in a research report on Thursday, October 17th. They set a "buy" rating and a $18.00 price objective for the company.
View Our Latest Stock Report on Mural Oncology
Institutional Investors Weigh In On Mural Oncology
A number of institutional investors have recently added to or reduced their stakes in the company. BBR Partners LLC bought a new position in shares of Mural Oncology in the second quarter valued at $31,000. Rhumbline Advisers bought a new position in shares of Mural Oncology in the second quarter valued at $34,000. Canada Pension Plan Investment Board bought a new position in shares of Mural Oncology in the second quarter valued at $70,000. Dimensional Fund Advisors LP bought a new position in shares of Mural Oncology in the second quarter valued at $71,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Mural Oncology in the second quarter valued at $84,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.
About Mural Oncology
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
